{"id":390818,"date":"2017-12-06T00:00:00","date_gmt":"2017-12-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/emthcg0002-2017-biopharma-multiple-sclerosis-emerging-therapies-zinbryta-daclizumab-us-wave-2-2017\/"},"modified":"2026-03-31T10:49:22","modified_gmt":"2026-03-31T10:49:22","slug":"emthcg0002-2017-biopharma-multiple-sclerosis-emerging-therapies-zinbryta-daclizumab-us-wave-2-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/emthcg0002-2017-biopharma-multiple-sclerosis-emerging-therapies-zinbryta-daclizumab-us-wave-2-2017\/","title":{"rendered":"Multiple Sclerosis | Emerging Therapies | Zinbryta (daclizumab) | US | Wave 2 | 2017"},"content":{"rendered":"<p>With its launch in August 2016, Zinbryta became the 14th disease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody boasts solid efficacy, infrequent dosing, and a novel anti-inflammatory mechanism of action, but the potential for serious long-term side effects has led to a restrictive U.S. label. DRG\u2019s launch-tracking series will examine how the perception and performance of Zinbryta evolves through one year postlaunch\u00a0in an MS market that, on the one hand, is increasingly transformed by a growing array of DMTs with compelling risk-benefit profiles, but on the other hand, can and will support a clinical role for each new agent in treating a heterogeneous disease with a complex natural history.<\/p>\n<p><strong>What you will learn in this content:<\/strong><\/p>\n<ul>\n<li>What is U.S. neurologists\u2019 awareness of and familiarity with Zinbryta, and what are their perceptions of the product?<\/li>\n<li>Among prescribers, for which patients are they prescribing Zinbryta, what are the reasons for prescribing, and how satisfied are they with Zinbryta?<\/li>\n<li>What are the promotional messages and activities that Biogen\/AbbVie\u00a0are employing in support of the Zinbryta launch?<\/li>\n<li>How do prescribers and nonprescribers compare across key metrics?<\/li>\n<li>How is the trial and adoption of Zinbryta tracking compared with other\u00a0product launches in the MS market?<\/li>\n<\/ul>\n<p><strong>Methodology: <\/strong>~75-100 U.S. neurologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten surveyed specialists participate in a 30-minute follow-up qualitative interview.<\/p>\n<p><strong>Key drugs:<\/strong> Zinbryta, Lemtrada, Tysabri, Ocrevus, Gilenya, Tecfidera, Copaxone, beta-interferons<\/p>\n<p><strong>Key companies:<\/strong> Biogen, AbbVie, Sanofi Genzyme, Novartis, Teva, Roche\/Genentech<\/p>\n<p><strong>Related reports: <\/strong>Emerging Therapies Zinbryta Wave 1, Emerging Therapies Lemtrada Waves 1-4<\/p>\n","protected":false},"template":"","class_list":["post-390818","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-product-emerging-therapies","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390818\/revisions"}],"predecessor-version":[{"id":393942,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390818\/revisions\/393942"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}